Business Context and Reporting Period
Aptevo Therapeutics Inc. (APVO) filed a Form 8-K on June 29, 2026, reporting the entry into a material definitive agreement. The Company is a biopharmaceutical firm focused on developing antibody therapeutics, headquartered in Seattle, Washington.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial disclosure relates to a specific funding agreement:
- Grant Amount: $1,499,951.00
- Funding Type: Reimbursement basis only
- Matching Requirement: Company must provide non-state contributions at least equal to the grant amount
- Project Duration: Expected to extend through June 2028
Material Changes
The material change reported is the execution of a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund. This agreement provides funding to support Investigational New Drug (IND)-enabling studies for APVO451, the Company's trispecific antibody candidate for solid tumor indications. No comparative financial data or prior period changes are disclosed in this document.
Guidance, Outlook, and Risks
Outlook and Milestones: Funding is contingent upon the achievement of specified milestones, reporting requirements, and compliance with applicable terms. Payments are made based on the reimbursement of eligible costs incurred under an approved budget.
Risks and Contingencies: The agreement includes provisions for termination for cause or failure to achieve project requirements. The Company retains ownership of intellectual property generated but must acknowledge Grantor support and adhere to commercialization and public benefit commitments.
Investor Verification Checklist
- Verify the Company's ability to secure the required matching non-state contributions equal to the $1,499,951 grant.
- Confirm the specific milestones and reporting requirements necessary to trigger reimbursement payments.
- Review the full text of the Grant Award Agreement (to be filed as an exhibit to the Form 10-Q for the quarter ended June 30, 2026) for detailed termination clauses.
- Monitor the progress of IND-enabling studies for APVO451 to assess the likelihood of achieving project goals by June 2028.